PharmaMar presents new results of lurbinectedin at the ASCO Symposium on Genitourinary Cancers
January 30, 2024 at 08:09 am EST
Share
PharmaMar (MSE: PHM) has presented two posters on Zepzelca (lurbinectedin) at the Genitourinary Cancers (GU) Symposium of the American Society of Oncology (ASCO), held between January 25 and 27 in San Francisco, USA.
One in reference to neuroendocrine prostate carcinoma and small cell prostate cancer and another on metastatic neuroendocrine carcinomas of the genitourinary tract.
The poster presented by Dr. Haley M. Meyer et al., from the Mayo Clinic in Arizona, is titled 'Lurbinectedin in Prostatic Small Cell and Neuroendocrine Carcinoma.' These types of prostate cancer are a high-grade invasive malignancy, distinct from prostatic adenocarcinoma and with behavior similar to small cell lung cancer (SCLC), in which second-line and subsequent treatments represent important clinical challenges. This study collects the experience in four academic centers of eighteen metastatic patients previously treated with a median of four systemic therapies before lurbinectedin. Among the results, a clinical benefit rate of 56.3% and a partial response was observed in 5 of 16 patients, 31%. In short, the study concludes that lurbinectedin is a treatment option. well tolerated and active treatment for patients with neuroendocrine prostate carcinoma and small cell prostate cancer.
Alan H. Bryce, MD, CPE, clinical director of City of Hope Cancer Center in Phoenix, commented that 'a rate of partial response of 31% and stable disease of an additional 25% is quite promising in this population with highly refractory disease.
Dr. Mohammad Jad Moussa, from the University of Texas MD Anderson Cancer Center, Houston, Texas, presented the poster 'Clinical efficacy of lurbinectedin in Metastatic Neuroendocrine Carcinomas of the genitourinary tract: Multi-institutional real-world experience ' . Neuroendocrine carcinomas of the genitourinary tract, including metastatic small cell neuroendocrine carcinomas and large cell neuroendocrine carcinomas, are rare aggressive malignancies. This is the first multicenter series of fourteen lurbinectedin-treated patients with metastatic genitourinary neuroendocrine carcinoma with encouraging responses close to those of SCLC in previously treated metastatic neuroendocrine carcinomas of the bladder. The study concludes that larger cohorts are needed to confirm the survival benefit and genetic analyzes to identify the characteristics of patients who respond, the authors commented.
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Companyâs product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.
PHARMA MAR, S.A. 
